Table 2. Opinions and previous experiences about falsified pharmaceuticals.
| widespread n (%) | uncommon n (%) | don’t know n (%) | p-value (b) | odds ratio [95%CI] | |
|---|---|---|---|---|---|
| A. Drugs | |||||
| All respondents (405) (a) | 93 (23.0) | 177 (43.7) | 135 (33.3) | ||
| Gender | |||||
| Female (212) | 48 (22.6) | 76 (35.9) | 88 (41.5) | 0.0003 | 0.454 [0.296:0.696] |
| Male (193) | 45 (23.3) | 101 (52.3) | 47 (24.4) | ||
| Age (years) | 0.607 (c) | ||||
| ≤30 (45) | 8 (17.8) | 15 (33.3) | 22 (48.9) | ||
| 31-40 (90) | 20 (22.2) | 47 (52.2) | 23 (25.6) | ||
| 41-50 (83) | 17 (20.5) | 37 (44.6) | 29 (34.9) | ||
| 51-60 (121) | 34 (28.1) | 49 (40.5) | 38 (31.4) | ||
| ≥61 (64) | 13 (20.3) | 28 (43.8) | 23 (35.9) | ||
| Role | |||||
| Owner/Director (225) | 53 (23.6) | 107 (47.5) | 65 (28.9) | 0.044 | 1.566 [1.033:2.374] |
| Employee (180) | 40 (22.2) | 70 (38.9) | 70 (38.9) | ||
| B. Other products | |||||
| All respondents (405) (a) | 94 (23.2) | 174 (43.5) | 135 (33.3) | ||
| Gender | |||||
| Female (212) | 54 (25.5) | 80 (37.7) | 78 (36.8) | 0.140 | 0.720 [0.475:1.092] |
| Male (193) | 40 (20.7) | 96 (49.7) | 57 (29.6) | ||
| Age (years) | 0.268 (b) | ||||
| ≤30 (45) | 10 (22.2) | 14 (31.1) | 21 (46.7) | ||
| 31-40 (90) | 15 (16.7) | 49 (54.4) | 26 (28.9) | ||
| 41-50 (83) | 15 (18.1) | 35 (42.2) | 33 (39.7) | ||
| 51-60 (121) | 43 (35.5) | 48 (39.7) | 30 (24.8) | ||
| ≥61 (64) | 10 (15.6) | 30 (46.9) | 24 (37.5) | ||
| Role | |||||
| Owner/Director (225) | 52 (23.1) | 108 (48.0) | 65 (28.9) | 0.044 | 1.566 [1.033:2.374] |
| Employee (180) | 42 (23.3) | 68 (37.8) | 70 (38.9) | ||
Notes: (a) 262 missing answers; (b) “widespread”/“uncommon” vs “don’t know”; (c) chi-square test for trend.